Skip to main content

Table 3 Mean frequency of CD45RO + and LAG3 + lymphocytes in patients with different clinicopathological features

From: Clinicopathological significance and prognostic role of LAG3 + tumor-infiltrating lymphocytes in colorectal cancer; relationship with sidedness

Parameters

CD45RO.CT

CD45RO.IM

LAG3.CT

LAG3.IM

Mean ± SD

P-value

Mean ± SD

P-value

Mean ± SD

P-value

Mean ± SD

P-value

Sex

 Male

45.00 ± 14.86

0.903ª

50.12 ± 12.90

0.041*

4.95 ± 10.06

0.696

5.27 ± 8.46

0.907

 Female

46.98 ± 12.57

54.62 ± 11.55

6.26 ± 12.70

5.71 ± 10.17

Age

  < 63

46.00 ± 13.11

0.857

52.00 ± 11.95

0.912

5.35 ± 11.22

0.531

4.47 ± 8.07

0.407

  ≥ 63

45.56 ± 14.84

 

51.76 ± 13.15

 

5.56 ± 11.13

 

6.33 ± 9.97

 

Tumor side

 Right

45.00 ± 13.75

0.448

49.55 ± 12.90

0.263ª

5.32 ± 11.38

0.807

6.96 ± 12.28

0.322

 Left

46.84 ± 13.75

 

53.42 ± 12.28

 

5.64 ± 11.20

 

4.39 ± 5.99

 

Tumor size

  < 5

44.82 ± 13.31

0.555

53.30 ± 13.11

0.240

6.21 ± 12.91

0.809

3.44 ± 6.95

0.024*

  ≥ 5

46.28 ± 14.60

 

50.70 ± 12.16

 

5.06 ± 9.85

 

6.96 ± 10.29

 

Differentiation grade

 Low grade

44.08 ± 12.16

0.113

52.17 ± 10.40

0.768

4.42 ± 9.84

0.369ª

5.38 ± 9.41

0.841

 Moderate to high grade

47.91 ± 15.87

 

51.50 ± 14.91

 

6.78 ± 12.54

 

5.53 ± 8.83

 

T stage

 T1/T2

44.46 ± 11.52

0.432

51.91 ± 9.97

0.979

6.42 ± 11.66

0.025*,ª

5.23 ± 6.58

0.603

 T3/T4

46.46 ± 15.15

 

51.85 ± 13.76

 

4.95 ± 10.88

 

5.56 ± 10.26

 

Lymph node involvement

 Absent

43.72 ± 13.50

0.016*

52.44 ± 12.92

0.461

6.15 ± 11.92

0.422

6.35 ± 10.63

0.335

 Present

49.78 ± 14.22

 

50.76 ± 11.83

 

4.11 ± 9.40

 

3.67 ± 4.66

 

M stage

 M0

45.52 ± 14.07

0.859ª

51.97 ± 12.78

0.556ª

5.45 ± 11.16

0.911ª

5.68 ± 9.44

0.278

 M1

48.33 ± 13.54

 

50.83 ± 10.18

 

5.58 ± 11.36

 

3.00 ± 4.43

 

TNM stage

 I/II

43.80 ± 13.85

0.037*

52.55 ± 13.27

0.421

6.38 ± 12.25

0.388

6.65 ± 10.92

0.200

 III/IV

48.94 ± 13.77

 

50.77 ± 11.30

 

3.98 ± 8.95

 

3.5000 ± 4.50

 

Lymphovascular invasion

 Absent

44.68 ± 12.20

0.287

51.58 ± 12.70

0.750

5.21 ± 11.01

0.301

5.99 ± 9.30

0.709

 Present

47.28 ± 16.15

 

52.28 ± 12.43

 

5.80 ± 11.39

 

4.70 ± 8.91

 

Perineural invasion

 Absent

44.59 ± 13.64

0.212ª

51.75 ± 12.73

0.818

5.63 ± 11.62

0.952

5.89 ± 9.84

0.667

 Present

51.00 ± 14.65

 

52.40 ± 11.91

 

4.72 ± 8.80

 

3.48 ± 4.46

 

Metastasis

 Absent

45.22 ± 13.35

0.595

51.85 ± 11.99

0.663

6.33 ± 12.30

0.055ª

6.28 ± 10.35

0.064

 Present

46.76 ± 16.69

 

50.73 ± 14.41

 

3.03 ± 7.22

 

2.97 ± 4.21

 

Recurrence

 Absent

45.10 ± 13.55

0.592

51.65 ± 12.18

0.928

6.49 ± 12.36

0.040*

6.38 ± 10.06

0.131

 Present

46.72 ± 16.49

 

51.89 ± 15.20

 

1.86 ± 2.86

 

2.96 ± 4.01

 

Survival

 Alive

44.87 ± 13.89

0.380

53.54 ± 12.61

0.068

6.28 ± 12.68

0.366

6.16 ± 10.85

0.158

 Dead

47.01 ± 14.16

 

49.56 ± 12.18

 

4.33 ± 8.52

 

4.45 ± 5.92

 
  1. CT Central of tumor, IM Invasive margin
  2. ªP-values were obtained from non-parametric Mann–Whitney test.*p < 0.05
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us